Home

Viatris Inc. - Common Stock (VTRS)

11.40
-0.02 (-0.22%)

Viatris Inc is a global healthcare company that focuses on providing access to medicines, including generic and specialty pharmaceuticals, to improve patient health outcomes worldwide

Formed from the merger of Mylan and Upjohn, a division of Pfizer, Viatris leverages its extensive portfolio to develop and manufacture a wide range of high-quality medications that address diverse therapeutic areas. With a commitment to sustainability and innovation, the company emphasizes collaboration with healthcare providers, policymakers, and communities to enhance the accessibility and affordability of essential healthcare solutions for patients around the globe.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close11.42
Open11.40
Bid11.39
Ask11.40
Day's Range11.21 - 11.43
52 Week Range9.925 - 13.62
Volume2,998,666
Market Cap13.81B
PE Ratio (TTM)-15.61
EPS (TTM)-0.7
Dividend & Yield0.4800 (4.21%)
1 Month Average Volume8,922,217

News & Press Releases

Current Report: Viatris Inctalkmarkets.com
Viatris Inc. is a wholly owned subsidiary of Pfizer that specializes in off-patent drugs. Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday’s market close.
Via Talk Markets · January 31, 2025
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Pricesbenzinga.com
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.
Via Benzinga · January 6, 2025
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and Morebenzinga.com
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Via Benzinga · December 22, 2024
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via MarketBeat · November 27, 2024
Peering Into Viatris's Recent Short Interestbenzinga.com
Via Benzinga · May 27, 2024
3 Chart Patterns That Cut Through The Market’s Chaostalkmarkets.com
There are endless ways of analyzing price data. But the truth is, I don’t use 90% of it. What I find most useful when analyzing stock charts is pattern recognition. Today, I’ll review three of the patterns that I use regularly in my trading research.
Via Talk Markets · November 16, 2024
Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spikebenzinga.com
The U.S.
Via Benzinga · November 7, 2024
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydownbenzinga.com
Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 guidance reaffirms strong growth outlook.
Via Benzinga · November 7, 2024
These 10 Stocks Were S&P 500's Worst Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?benzinga.com
The S&P 500 enjoyed a strong year in 2021, the first year with Joe Biden in the White House. Not all stocks were up and past results could show sectors to avoid ahead of the 2024 election.
Via Benzinga · November 2, 2024
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetesbenzinga.com
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.
Via Benzinga · November 1, 2024
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Via News Direct · October 1, 2024
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?benzinga.com
Regeneron filed an appeal after a court's decision, which was issued under seal.
Via Benzinga · September 24, 2024
EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witchingbenzinga.com
CC Lagator of Options AI warns traders to expect increased volatility in the week after September's 'triple witching,' with over $5 trillion in options expiring and historical evidence of market turbulence. VIX at 16 presents attractive opportunities for call option buyers.
Via Benzinga · September 20, 2024
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stabilitybenzinga.com
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.
Via Benzinga · September 6, 2024
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Productionbenzinga.com
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.
Via Benzinga · September 6, 2024
3 Top Value Stocks to Buy Right Nowfool.com
Value stocks offer potential for significant returns in today's overheated market.
Via The Motley Fool · August 20, 2024
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · August 15, 2024
Why Viatris Stock Is Jumping Todayfool.com
Investors are applauding the healthcare company's improving growth story.
Via The Motley Fool · August 8, 2024
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugsbenzinga.com
Viatris reports Q2 revenue of $3.78 billion, with strong growth in Greater China and new product launches driving results. Adjusted EPS of $0.69 beats estimates, and the company raises its 2024 sales outlook to $14.6 -$15.1 billion.
Via Benzinga · August 8, 2024
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugsbenzinga.com
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Via Benzinga · August 6, 2024
3 Surprisingly Underrated Stocks to Buy Right Nowfool.com
These stocks arguably deserve more respect from investors.
Via The Motley Fool · July 26, 2024
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?benzinga.com
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your portfolio?
Via Benzinga · July 21, 2024
S&P 500 Four Under Fivetalkmarkets.com
The S&P 500's strong first half, with gains exceeding 15%, has pushed its valuation even higher.
Via Talk Markets · June 28, 2024
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecastbenzinga.com
Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.
Via Benzinga · May 9, 2024
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?benzinga.com
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve interest rate cuts.
Via Benzinga · May 9, 2024